|Bid||1.1100 x 1400|
|Ask||1.2700 x 2200|
|Day's Range||1.1000 - 1.1800|
|52 Week Range||1.0300 - 4.2553|
|Beta (5Y Monthly)||0.15|
|PE Ratio (TTM)||7.59|
|Earnings Date||Mar 09, 2020 - Mar 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 10, 1980|
|1y Target Est||19.00|
Spherix Incorporated (Nasdaq: SPEX) today announced that it has closed the CBM BioPharma, Inc. transaction and is working to develop these cancer drugs.
Spherix Incorporated (Nasdaq: SPEX) announced today that additional patent coverage has been granted by the United States Patent & Trademark Office to the patent portfolio being acquired by Spherix, in the field of pancreatic cancer.
NEW YORK, Oct. 21, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution. As we accelerate our transformation into an innovative biotech company, I believe this is the optimal time to provide our shareholders with a detailed update. I am excited at the potential for Spherix and believe we have put several important pieces in place to drive future success. First, October 21, 2019 is the record date for our dividend distribution. If you are a shareholder of record at 5 p.m. Eastern Standard on that date, you will receive one share of Hoth Therapeutics, Inc common stock for every 29 shares of Spherix common stock you own. The distribution of the Hoth shares is currently anticipated to occur on or about October 28, 2019, subject to effectiveness of the registration statement for such shares.
NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that its stock has been upgraded to a "buy" rating from a "hold" rating in a research note ...
It is not often in the pages of the Emerging Markets Report do we get the opportunity to tell our readers that a Company is giving back roughly $425,000* worth of value to its shareholders. Every Spherix stockholder will be entitled to receive one share of Hoth common stock for every twenty-nine shares of Spherix common stock held as of 5 p.m. Eastern Time on October 21, 2019. Extrapolating from that model, ten thousand shares of Spherix at a cost basis of $16,900 earns the owner 344 Hoth shares worth $1,482 on paper.
NEW YORK, Oct. 11, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that on October 2, 2019, the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 100,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix. Each Spherix stockholder will be entitled to receive one (1) share of Hoth common stock for every twenty-nine (29) shares of Spherix common stock held as of 5 p.m. Eastern Time on October 21, 2019, the record date.
When Botox hit the annals of pop culture as a beauty product, a healer, and more it was shocking to many. Today it appears that deadly Anthrax may be breaking good as Botox has, intent on joining the ranks of the helpful and the healers while eschewing its well-earned infamy for contributing to the actual Fall of Rome and more recently, a domestic bio-terrorism event that had the nation on edge. Indeed, U.S. based Spherix Inc. (SPEX) believes that Anthrax could very well be used to effectively fight ovarian cancer.
NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution. As previously stated, Spherix is moving forward with the distribution of 100,000 shares of common stock of Hoth Therapeutics, Inc. to its shareholders. Spherix's Board of Directors will meet to set a record date for the stock dividend.
The Option includes rights to U.S. Patent Application Serial No. 15/747,255, which is currently under active examination at the U.S. Patent and Trademark Office. Under the Option, Spherix has until early December of 2019 to complete its due diligence and execute a license agreement for commercial development.
NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor. Spherix's Option includes two issued patents, United States Patent Nos. Under the Option, Spherix has until late November to complete its due diligence and execute a license agreement for commercial development.
At the Meeting, the Company's shareholders approved the issuance of shares of our Common Stock, including shares of our common stock underlying Series L convertible preferred stock, to be issued by us pursuant to the terms of that certain Asset Purchase Agreement, dated May 15, 2019, by and between the Company and CBM BioPharma, Inc., as amended by Amendment No. 1 to the Asset Purchase Agreement, dated May 30, 2019, in an amount equal to or in excess of 20% of our common stock outstanding before the issuance of such common stock and such Series L convertible preferred stock (including upon the operation of anti-dilution provisions contained in such Series L convertible preferred stock). Shareholders also approved the amendment to the Company's Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of common stock from 100,000,000 to 99,000,000.
In advance of our Special Meeting on September 5th, I write to update you on certain developments and to encourage you to vote in favor of the proposals recommended by the Board of Directors and set forth in the Special Meeting Proxy. The acquisition of the CBM BioPharma, Inc. ("CBM") pharmaceutical assets is an integral step in building Spherix into a cutting edge pharmaceutical company. It also builds upon the success we have already realized as a part of the Company's transformation. Two years ago, Spherix made an investment in Hoth Therapeutics, Inc., which is now estimated to be worth over $10,000,000. In our effort to deliver value to our shareholders and to continue the transformation at Spherix, the Board intends to propose a special dividend of One Hundred Thousand shares (100,000) of Hoth stock.
CBM Bolsters Intellectual Property Asset Portfolio NEW YORK , June 26, 2019 /PRNewswire/ -- CBM BioPharma Inc. ("CBM") today announced that the United States Patent & Trademark Office (USPTO) ...
NEW YORK, June 19, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has filed a Preliminary Proxy Statement with the Securities and Exchange Commission and announced a Special Meeting of Stockholders related to approving various items related to the proposed and previously announced acquisition of substantially all of the assets of CBM BioPharma, Inc. ("CBM"). The acquisition of the CBM assets constitutes another step in Spherix's continued transformation into an innovative pharmaceutical company with pioneering drugs and treatments focused on the development and commercialization of oncology therapeutics. CBM is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas.
MIAMI BEACH, FL / ACCESSWIRE / June 11, 2019 / Emerging stocks rarely provide more than a single compelling reason for investment. Having completed a recapitalization in May of 2019 that leaves SPEX with just over two million shares outstanding, the company's strategy to identify and invest in cutting-edge technology is already proving to be a profitable business model for SPEX.
LAS VEGAS, NV / ACCESSWIRE / June 6, 2019 / In October of last year, StockLab's editorial team was introduced to Spherix Incorporated (SPEX). Frankly, it's tough to top a Spherix acquisition target restoring mobility to a nearly paralyzed rodent but last week's quarterly report perhaps rivals the moving mouse insofar as financial statements go. The Company has total assets of $11,937,000.
Agreement to Acquire Assets of CBM BioPharma, Inc. In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
ORLANDO, FL / ACCESSWIRE / April 10, 2019 / In today's issue of SmalCap Sentinel, we get the opportunity to virtually sit down with Spherix Incorporated (SPEX) CEO, Anthony Hayes. It has been an eventful year for Hayes and Spherix, much of which Hayes covered in a wide-ranging recent shareholderletter.
ORLANDO, FL / ACCESSWIRE / April 3, 2019 / By any measure, Spherix Incorporated (NASDAQ: SPEX) has had a very good year. It is not often one can say at their annual meeting that the Company posted a one-time gain of $7.5 million and p.s., our science looks like it restored mobility to a mouse paralyzed by Acute Lymphoblastic Leukemia. With Spherix now booking total assets of $13.3 million, less than 9 million shares outstanding and zero debt, CEO Anthony Hayes has likely engendered some goodwill from his shareholder base.
One of the most challenging tasks as CEO is taking the vision of the Board and transferring that into meaningful value for our shareholders. However, 2018 marked a pivotal year for our Company as we forged ahead with the vision of creating an exciting biotechnology company. With more than $13,000,000 in assets and less than 9,000,000 in outstanding shares, we are moving Spherix in the right direction. The CBM transaction, announced in October of last year, brings to Spherix exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. Significant progress has already been made.
ORLANDO, FL / ACCESSWIRE / March 13, 2019 / In the world of smaller equities, revenue, especially for emerging biotech or tech companies, can be fleeting, rare even. As such, Spherix Incorporated (SPEX) posting a one-time gain of $7.5 million in its 10-K should turn a few heads. It is notable that the $7.5 million one-time gain comes from an investment the Company and Spherex CEO Anthony Hayes made two years ago, putting $670k into a then private biotech called Hoth Therapeutics where Hayes saw potential and promise.
NEW YORK , March 12, 2019 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX)- a technology development company committed to the fostering of innovative ideas, announced today that it has filed its Annual ...